Identification and stratification of systemic lupus erythematosus patients into two transcriptionally distinct clusters based on IFN-I signature.


Journal

Lupus
ISSN: 1477-0962
Titre abrégé: Lupus
Pays: England
ID NLM: 9204265

Informations de publication

Date de publication:
Apr 2021
Historique:
pubmed: 27 1 2021
medline: 7 10 2021
entrez: 26 1 2021
Statut: ppublish

Résumé

Despite the significant advancement in the understanding of the pathophysiology of systemic lupus erythematosus (SLE) variable clinical response to newer therapies remain a major concern, especially for patients with lupus nephritis and neuropsychiatric systemic lupus erythematosus (NPSLE). We performed this study with an objective to comprehensively characterize Indian SLE patients with renal and neuropsychiatric manifestation with respect to their gene signature, cytokine profile and immune cell phenotypes. We characterized 68 Indian SLE subjects with diverse clinical profiles and disease activity and tried to identify differentially expressed genes and enriched pathways. To understand the temporal profile, same patients were followed at 6 and 12-months intervals. Additionally, auto-antibody profile, levels of various chemokines, cytokines and the proportion of different immune cells and their activation status were captured in these subjects. Multiple IFN-related pathways were enriched with significant increase in IFN-I gene signature in SLE patients as compared to normal healthy volunteers (NHV). We identified two transcriptionally distinct clusters within the same cohort of SLE patients with differential immune cell activation status, auto-antibody as well as plasma chemokines and cytokines profile. Identification of two distinct clusters of patients based on IFN-I signature provided new insights into the heterogeneity of underlying disease pathogenesis of Indian SLE cohort. Importantly, patient within those clusters retain their distinct expression dynamics of IFN-I signature over the time course of one year despite change in disease activity. This study will guide clinicians and researchers while designing future clinical trials on Indian SLE cohort.

Identifiants

pubmed: 33497307
doi: 10.1177/0961203321990107
doi:

Substances chimiques

Autoantibodies 0
Cytokines 0
Interferon Type I 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

762-774

Auteurs

Vineeta Shobha (V)

St. John's National Academy of Health Sciences, Bangalore, India.

Anu Mohan (A)

St. John's National Academy of Health Sciences, Bangalore, India.

A V Malini (AV)

Bristol-Myers Squibb, Mumbai, India.

Puneet Chopra (P)

Biocon Bristol-Myers Squibb R&D Centre, Syngene International Ltd., Bangalore, India.

Preethi Karunanithi (P)

Biocon Bristol-Myers Squibb R&D Centre, Syngene International Ltd., Bangalore, India.

Siva Subramani Thulasingam (S)

Biocon Bristol-Myers Squibb R&D Centre, Syngene International Ltd., Bangalore, India.

Sabariya Selvam (S)

Biocon Bristol-Myers Squibb R&D Centre, Syngene International Ltd., Bangalore, India.

Avisek Deyati (A)

Biocon Bristol-Myers Squibb R&D Centre, Syngene International Ltd., Bangalore, India.

Ratika Srivastava (R)

Biocon Bristol-Myers Squibb R&D Centre, Syngene International Ltd., Bangalore, India.

Sushma Basavanthappa (S)

Biocon Bristol-Myers Squibb R&D Centre, Syngene International Ltd., Bangalore, India.

Nadine Lemos (N)

Biocon Bristol-Myers Squibb R&D Centre, Syngene International Ltd., Bangalore, India.

S Margaret Sunitha (SM)

Biocon Bristol-Myers Squibb R&D Centre, Syngene International Ltd., Bangalore, India.

Debarati Mazumder Tagore (D)

Biocon Bristol-Myers Squibb R&D Centre, Syngene International Ltd., Bangalore, India.

Amit Anand (A)

Biocon Bristol-Myers Squibb R&D Centre, Syngene International Ltd., Bangalore, India.

Saumya Pant (S)

Bristol-Myers Squibb, Mumbai, India.

Vivek Jayaswal (V)

Biocon Bristol-Myers Squibb R&D Centre, Syngene International Ltd., Bangalore, India.

Manjunath Ramarao (M)

Bristol-Myers Squibb, Mumbai, India.

Shailesh Dudhgaonkar (S)

Biocon Bristol-Myers Squibb R&D Centre, Syngene International Ltd., Bangalore, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH